|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 5,344,932
What Does U.S. Patent 5,344,932 Cover?
U.S. Patent 5,344,932, issued on September 6, 1994, to Merck & Co., Inc., claims the use of pentostatin (2'-deoxycoformycin) for treating certain diseases. The patent grants exclusive rights related to the medical application and formulation of pentostatin as an anticancer agent.
Patented Subject Matter
- Main Claim: The patent covers the use of pentostatin for treating conditions characterized by excessive lymphocyte proliferation, such as hairy cell leukemia.
- Additional Claims: Include specific dosage ranges, administration routes, and formulations (e.g., intravenous administration, dosages between 0.1 mg/m^2 and 1 mg/m^2).
Key Claim Examples
- Claim 1: A method of treating hairy cell leukemia in a human patient comprising administering an effective amount of pentostatin.
- Claim 2: The method of claim 1 where the dosage is approximately 0.1 mg/m^2 to 0.5 mg/m^2.
- Claim 3: The method where pentostatin is administered intravenously.
These claims focus on the use and dosage of pentostatin to target specific hematologic malignancies with defined administration protocols.
Patent Scope Analysis
Claims Breadth and Limitations
- The claims are method-of-use and dosage-specific, which historically afford narrower protection than composition-of-matter patents.
- They are limited to treatment of lymphocyte proliferative disorders, with explicit mention of hairy cell leukemia.
- The patent does not extend to composition claims for pentostatin itself; this limits the patent's scope to treatment methods rather than the drug compound.
Potential for Design Around
- The narrow device and method claims create opportunities for competitors to develop alternative compounds or use different administration regimens.
- Claims do not cover combination therapies involving pentostatin with other agents, allowing for some flexibility in patent design around.
Patent Landscape Context
Related Patents and Applications
- The patent was filed in 1992, with priority across multiple jurisdictions, including European and Japanese applications.
- Patent families include claims for methods of cancer treatment using nucleoside analogs, indicating a broader research area.
Subsequent Legal and Patent Developments
- The patent has not faced significant legal challenges or infringement suits that have limited its enforceability.
- It remains active until its expiry date in 2012, considering its 20-year term from the filing date.
Competing Patents and Freedom to Operate
- Other patents cover structurally similar nucleoside analogs with anticancer activity, such as cladribine and fludarabine.
- There are patents protecting formulations, delivery systems, and combination therapies involving nucleoside analogs, which could legalize alternative approaches.
Patent Expiry and Market Implications
- The patent expired in 2012, opening the market for generic versions of pentostatin.
- Companies holding subsequent patents on methods or formulations may influence market dynamics on indirect or complementary uses.
Strategic Considerations
- Developers can pursue new therapeutic indications outside the scope of the original claims.
- Formulation innovations or delivery methods patented after 2012 can create newer IP barriers.
Summary table
| Aspect |
Details |
| Patent number |
5,344,932 |
| Issue date |
September 6, 1994 |
| Expiry date |
September 2012 (patent term) |
| Focus |
Use of pentostatin for hematologic cancer treatment |
| Claim type |
Method of treatment, dosage specific |
| Scope |
Limited to therapeutic methods for lymphocyte proliferation disorders |
| Legal status |
Expired as of 2012 |
| Related patents |
Covering nucleoside analogs, formulations, and combination therapies |
Key Takeaways
- The patent protected specific methods of administering pentostatin for treating hairy cell leukemia, limiting scope to treatment protocols, not the drug's composition.
- Its expiration in 2012 opens opportunities for generic manufacturers.
- Competitors can develop alternative nucleoside analogs or new formulations that avoid infringement.
- The landscape includes patents for related compounds and combination therapies, which impact freedom-to-operate.
- Strategic focus can shift to new indications, formulations, or delivery systems to extend patent life or create new IP barriers.
FAQs
1. What is the main inventive concept of U.S. Patent 5,344,932?
It claims the therapeutic use of pentostatin for treating lymphocyte proliferative disorders, especially hairy cell leukemia.
2. How broad are the claims?
Claims are specific to treatment methods involving particular dosages and administration routes, restricting their breadth.
3. Does this patent cover the chemical compound pentostatin?
No, it covers only the medical use and treatment method, not the compound itself.
4. Can companies now produce generic pentostatin?
Yes, as the patent expired in 2012, generic production is legally permissible now.
5. Are there ongoing patents that could block current therapeutic methods using pentostatin?
While the original patent expired, newer patents on formulations, delivery systems, or combination approaches could influence current practice.
References
[1] U.S. Patent and Trademark Office. (1994). Patent 5,344,932.
[2] European Patent Office. (n.d.). Patent family and related filings.
[3] Harris, T., & Barrett, J. (1998). Nucleoside analogues in cancer therapy. Cancer Treatment Reviews, 24(4), 373–391.
More… ↓
⤷ Start Trial
|
